Quantcast

Latest Antibiotic-resistant bacteria Stories

2014-07-29 12:36:03

ROCKVILLE, Md., July 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange") has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity....

2014-07-16 08:29:22

SER-109 demonstrated remarkably high clinical cure rate and excellent safety profile CAMBRIDGE, Mass., July 16, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has completed enrollment for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic designed for the treatment of recurrent Clostridium difficile Infection...

2014-07-07 16:23:01

LONDON, July 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:MarketVIEW: Clostridium difficile vaccines http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_clostridium_difficile_vaccines.htmlClostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients...

2014-07-07 12:28:56

To Effectively Compete with Current Anti-MRSA Therapies, Emerging Agents Will Need to be Amenable to Outpatient Use, According to Findings from Decision Resources Group BURLINGTON, Mass., July 7, 2014 /PRNewswire/ -- Decision Resources Group finds that, although vancomycin continues to be the standard-of-care for infections caused by methicillin-resistant Staphylococcus aureus (MRSA), there is growing concern among infectious disease (ID) specialists over rising vancomycin minimum inhibitory...

2014-07-07 12:28:38

Company's Breakthrough Innovation to Enable First Therapeutics for Microbiome-based Diseases CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical composition patent application that covers its lead product candidate, SER-109, which is currently...

2014-06-30 12:32:12

VANCOUVER, Wash., June 30, 2014 /PRNewswire/ -- SteriWeb Medical has announced FDA over the counter clearance for Omnicide Antimicrobial Gel , a long-lasting, non-antibiotic, petrolatum based topical gel with proven effectiveness against even the most resistant, virulent bacteria, such as MRSA, VRE, and CRE. Laboratory data has also demonstrated complete effectiveness against pathogenic fungi, molds, and yeasts, rendering Omnicide an appropriate choice for a wide variety of clinical...

2014-06-30 08:29:30

-- Company Expects to Initiate C. difficile Clinical Trials in 2014 -- ROCKVILLE, Md., June 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating...

2014-06-19 04:21:30

LAUSANNE, Switzerland, June 19, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known...

2014-06-18 16:26:41

GERMANTOWN, Maryland, and HILDEN, Germany, June 18, 2014 /PRNewswire/ -- - Assay offers faster quantification of CMV DNA levels in patient samples - Up to 60% of all transplant patients are repeatedly tested for CMV viral load to help avoid potentially life-threatening conditions caused by this virus - PMA approval of artus(R) CMV RGQ MDx Kit adds further value to the QIAsymphony modular family of automated instruments as the...

2014-06-09 08:28:32

GLASGOW, Scotland, June 9, 2014 /PRNewswire/ -- Grant to help fund Phase I trial with lead candidate oral MGB-BP-3 for Clostridium difficile MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that it has been awarded a GBP1.3 million conditional grant from the Technology Strategy Board, the UK's innovation agency, under its Biomedical Catalyst programme. The grant will...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related